– CNBC
Ionis Pharmaceuticals, Inc. Announces The Journal Of The American Medical Association Published Results From The Phase 3 NEURO-TTRansform Study Of Eplontersen, An Investigational Treatment For Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Publication of NEURO-TTRansform study in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen halted disease progression and continuously improved quality of life at 35-,
